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ABSTRACT
Post‐myocardial infarction (MI), overactive inflammation is the hallmark of aging, however, the mechanism is
unclear. We hypothesized that excess influx of omega 6 fatty acids may impair resolution, thus impacting the
cardiosplenic and cardiorenal network post‐MI. Young and aging mice were fed on standard lab chow (LC) and
excess fatty acid (safflower oil; SO)‐enriched diet for 2 months and were then subjected to MI surgery. Despite
similar infarct areas and left ventricle (LV) dysfunction post‐MI, splenic mass spectrometry data revealed higher
levels of arachidonic acid (AA) derived pro‐inflammatory metabolites in young‐SO, but minimal formation of
docosanoids, D‐ and E‐ series resolvins in SO‐fed aged mice. The aged mice receiving excess intake of fatty acids
exhibit; 1) decreased lipoxygenases (5‐,12‐, and 15) in the infarcted LV; 2) lower levels of 14HDHA, RvD1, RvD5,
protectin D1, 7(S)maresin1, 8‐,11‐,18‐HEPE and RvE3 with high levels of tetranor‐12‐HETEs; 3) dual population
of macrophages (CD11blow/F480high and CD11bhigh/F480high) with increased pro‐inflammatory
(CD11b+F4/80+Ly6Chi) phenotype and; 4) increased kidney injury marker NGAL with increased expression of
TNF‐α and IL‐1β indicating MI‐induced non‐resolving response compared with LC‐group. Thus, excess fatty acid
intake magnifies the post‐MI chemokine signaling and inflames the cardiosplenic and cardiorenal network
towards a non‐resolving microenvironment in aging.

INTRODUCTION
Heart failure (HF) is an enormous medical burden and
the leading cause of mortality in aging populations [1].
Nearly 2% of the US population, almost 5 million
people, are affected with HF as an age-related disease
following myocardial infarction (MI) [1, 2]. Post-MI,
the acute response is from the spleen to direct early
healing, but the chronic supply of neutrophils and
monocyte/macrophages triggers the non-resolving
response that progresses to HF [3-6]. Perturbed or
dysregulated healing post-MI is characterized by
marked inflammation and coronary syndrome
pathology, leading to non-resolving inflammation [5, 79]. Lipoxygenase (LOX) enzymes remodel fatty acids
and program the non-resolving or resolving
inflammation response post-MI, thus the enzymesubstrate availability or substrate imbalance defines the
formation of pro-inflammatory or resolving mediator(s)
post-MI [5, 8]. With application of mass spectrometry-
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based structural elucidation, it is now validated that
omega-3 and omega-6 fatty acids are biosynthetic
precursors of resolvins, maresin, protectins and
lipoxins, with inflammation-resolving properties [10].
Omega-6 plays an essential role in health homeostasis,
however, we found that chronic, excessive intake of
omega-6 leads to progression of non-resolving
inflammation in obese aging mice, post-MI and
development of bone marrow adiposity [5, 11]. Recent
evidence suggests that MI-induced events are a major
sign of metabolic disarray in the LV healing with
limited generation of resolving lipid mediators,
resulting in non-resolving inflammation, though the
mechanism(s) is unclear. [5, 12, 13]. Several studies
have explored derangements of glucose and fatty acids
to define the role of lipotoxicity, glucotoxicity, or
glucolipotoxicity in HF progression [14]. Proteomics
and metabolomics databases indicate that substrate
variability, such as fatty acids, amino acids, protein, and
glucose, regulates cardiac remodeling following MI
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[12]. The fundamental limitation of the currently
published knowledge is the lack of data in regards to
which specific pathway to target for enzyme(s)
individually or grouped. This information could be
essential for discovering therapeutic treatments for the
millions of aging patients at risk of HF post-MI to
resolve their inflammation and potentially halt the life
threatening progression to HF.
LOXs (-5, -12 and -15) are lipid-busting enzymes that
use fatty acids to synthesize bioactive molecules in
response to myocardial stress or injury [8, 15]. Post-MI,
LOX-derived
specialized
mediators/biomolecules
facilitate immune cell phenotypes, residual time at the
site of injury and their kinetics in order to repress or
progress inflammation to modulate LV healing [5, 8].
Data has suggested that LOXs are increased in the
failing heart [13], but the details of how excess intake
of omega-6 fatty acids affects resolving/non-resolving
bioactive(s) are unclear. Excess intake of omega-6 not
only alters bone marrow myeloid milieu, but also
decreases lifespan, aggravates non-resolving inflammation, and develops nephropathy in lupus-prone
inflamed mice, [11, 16] therefore the present report
investigated the cardiorenal network in HF pathology.
To investigate the chemical nature of cardiorenal HF
and to integrate the translational outlook of obesity
superimposed on aging, we determined the fatty acids
involved in remodeling post-MI in young adults (6
month) and aging (18 month) mice using liquid
chromatography–mass spectrometry (LC-MS/MS)
metabololipidomics methodology. Here, we hypothesized that excess intake of omega-6 alters the balance
of pro-inflammatory and pro-resolving metabolites
post-MI in aging, thereby driving non-resolving
inflammation in the cardiosplenic and cardiorenal
networks. Post-MI, in highly oxidative settings, an
excess influx of omega-6 fatty acids reduces primarily
D- (RvD1, RvD5) and E- (RvE3) series resolvins, 7(S)
maresin, protectin D1, and other resolving precursors,
such as 4-, 10-, 14-HDHA and 8-,11-,18- HEPE during
the acute inflammatory phase and are essential to the
pro-resolving response. Thus, an imbalance of these
mediators resulted in the accumulation of proinflammatory macrophages (CD11b+F4/80+Ly6Chi) in
the infarcted LV, leading to signs of MI-induced nonresolving inflammation. Despite the positive benefit of
omega-6 fatty acids in cardiovascular health, excess or
imbalanced intake dysregulates LOXs in the infarcted
LV, leading to an insufficiency of resolving bioactives
and, thereby, impaired resolution. Thus, post-MI, the
non-resolving or pro-inflammatory macrophage
phenotype depends on the eicosanoids and docosanoids present in the transcellular splenic milieu,
interlinked with lipid signaling, inflammation, and
LOXs activity.
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RESULTS
MI-induced LV dysfunction and excess fatty
acids reduced LOXs post-MI superimposed on
aging
The robust post-MI LV chamber dilation response and
wall thinning was observed within 24 hr in young and
aging mice (Figure 1). These changes were marked by
reduced LV fractional shortening at day (d) 1 in young
and aging mice compared to naïve controls (Table 1).
Post-MI, infarcted LV wall thinning was characterized
by loss of glycogen content (pink area) using periodic
acid schiff staining (PAS) compared to d0 naïve
controls (Figure 1B). MI-induced compensatory
hypertrophy of remote myocardium thickening was
notable in young mice, but relatively less in SO-aging
with marked thinning. The infarcted zone of necrotic
myocardium was resorbed in all four groups post-MI.
At the gene expression level, the aging mice on normal
diet reduced level of LOXs (5-, 12-, and 15-) mRNA
expression compared with young mice on standard diet .
Further, excess intake of fatty acids in both young and
aging mice displayed a decrease in LOX-15 and LOX-5
compared with respective controls on standard LC diet.
Excess fatty acid diet in young mice reduced LOX-12
expression compared with their aged match control on
normal diet, however no change was observed in LOX12 expression in aging mice fed either normal or high
fatty acid diet (Figure 1C). Since leukocyte derived proinflammatory cytokines contribute to the development
of the inflammatory response post-MI, we measured
TNF-α levels. The TNF-α levels were increased as an
impact of aging and due to excess omega-6 fatty acids
intake. Aging mice on SO diet displayed (4.5 fold;
p<0.5) increase in TNF-α expression compared with
young-SO cohorts (Figure 1C). Collectively, excess
influx of fatty acids in aging reduced LOX expression
with increased inflammation in LV healing post-MI.
Aging impacts cardiosplenic metabolome post-MI in
excess fatty acids fed mice
Post-MI, fatty acids remodel into several bioactive
molecules that temper the repression or progression of
resolution of inflammation in HF pathophysiology [8,
10]. To understand how the fatty acids remodel into
eicosanoids and docosanoids using LOXs in young and
aging mice post-MI, we used an unbiased, targeted
multiple reaction monitoring (MRM) LC-MS/MS
approach to resolve the splenic metabolites. We
analyzed 117 lipid analytes from young and aging mice,
with and without fatty acid supplement diet, at d0 and
post-MI d1. The main goal of the study was to focus on
MI-induced inflammation and lipid remodeling
(pathological). Therefore, we focused on post-MI lipid
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modifications, but to assess the bioavailability of diet
enrichment and its impact on LV-splenic network, we
analyzed limited pre-MI samples (physiological;
Supplementary Table 1). As an impact of aging, 18% of

eicosanoids were decreased post-MI. The excess fatty
acid supplements led to a robust increase in the levels of
eicosanoids both in young and aging cohorts before MI,
while the eicosanoids were decreased globally post-MI

Table 1. Necropsy and echocardiography parameters indicating reduced LV remodeling, pulmonary
edema and LV function in young and aged SO‐fed and LC‐fed mice post‐MI.
No-MI
Parameters

YoungLC
(n=19)

YoungSO
(n=13)

MI day 1

AgingLC
(n=11)

AgingSO
(n=13)

YoungLC
(n=7)

YoungSO
(n=9)

AgingLC
(n=9)

AgingSO
(n=14)

Necropsy parameters
Body weight (g)

34 ± 1

31 ±1

36 ± 2

34 ± 1

29 ± 1

30 ± 1

35 ± 3

35 ± 1

LV (mg)

74± 5

62 ± 2

114 ± 6

99 ± 3

108 ± 5

88 ± 3

115 ±6

105 ± 4

LV/BW:LV/Tibia

0.6± 0.01

0.6 ±

0.7 ±

0.8 ±

0.6 ±

0.6 ±0

0.5 ±0

0.5 ±0.1

0.01

0.01

0.03*

0.01

.01*

.01

0.6± 0.01

0.6 ±

0.6± 0.01

0.7 ±

(mg/g)
RV/BW (mg/g)

0.6 ±
0.01

Lung weight

0.02

0.8 ± 0.02 0.6 ±0.02

0.6 ±0.01

0.01

5.5± 1

5.4 ± 0.1

4.1 ± 0.2

4.7 ± 0.2

5.4 ± 0.1

5.8 ± 0.8

6.2 ± 1

6 ±1

Tibia (mm)

17 ± 0.2

17 ± 0.2

17 ± 0.6

17± 0.4

17 ± 0.2

17 ± 0.1

17 ± 0.2

17 ± 0.2

Infarct area (%)

ND

ND

ND

ND

53 ± 2

53 ±1

50 ±1

49 ±1

/Body weight
(mg/g)

Echocardiography parameters
Heart Rate (bpm)

452 ± 17

456 ± 20

473 ± 17

427 ± 7

450 ± 20

471 ± 20

461 ± 8

520 ± 12

EDV (ul)

82 ± 7

65 ± 5

72 ± 5

69 ± 4

79 ± 50

74 ± 4

89 ± 5

82 ± 5

ESV (ul)

35 ± 5

26 ± 2

35 ± 4

30 ± 3

65 ± 2*

58 ± 4*

74 ± 3*

67 ± 5*

Fractional

30 ± 2

31 ± 1

27 ± 1

30 ± 2

8 ± 1*

10 ± 1*

7 ± 2*

11± 1*

PWTs (mm)

0.67 ±

0.66 ±

0.71 ±

0.68 ±

0.48 ±

0.50±

0.55 ±

0.57 ±

Infarcted wall

0.03

0.04

0.05

0.04

0.04*

0.038

0.068

0.048

Shortening %

Values are means ± SEM. * p<0.05 vs young‐LC, ‘n’ indicates sample size; LV, Left Ventricle; BW. Body weight; RV,
Right Ventricle; ‐ = No infarct in d0 naïve controls; bpm, beats per minute; EDV, end‐diastolic volume; ESV, end‐
systolic volume; PWT, posterior wall thickness, S, systole; mm, millimeter
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(Figure 2A; heat map, Supplementary Table 1). Further,
supplementation of excess fatty acids in aging mice led
to decrease in 90% of eicosanoids level compared with
young–SO mice. Post-MI d1, heat map cluster analysis
and the Venn diagram (Figures 2A and B) showed that
the nearly 106 eicosanoids are impacted by age and
excess intake of fatty acids. A total of 19 eicosanoids
were changed as a result of aging, however, excess fatty
acid intake, irrespective of age, influenced 38 metabolites. The levels of 49 eicosanoids were changed due
to combined effect of both aging and excess of fatty
acid intake. Principal component analysis (PCA) for
global changes showed that young and aging cohorts on
standard LC diet were closely associated. The diverse
response to MI is indicated by the differential lipidomics
profiling in young and aging cohorts due to excess influx
of excess omega-6 fatty acids Figure 2C-D).
Aging dysregulated AA-derived metabolites post-MI
Prior to MI (d0), there was no difference observed
between groups in the levels of arachidonic (AA) acid
metabolites, 9,10-EpOME, PGA2, PGE2, TXB2 and
epoxyeicosatrienoic acids (EETs). The excess fatty acid
intake impacted AA acid metabolism leading to increas-

ed levels 9,10-EpOME, PGA2, PGE2, TXB2 and EETs in
both young and aging mice (Supplementary Table 1).
Post-MI aging impacted the maximum number of
eicosanoids that belongs to AA class. Overall levels of
the respective eicosanoids decrease post-MI. Compared
with young-LC mice, there was a further decrease in
levels of eicosanoids in aging-LC mice. The excess
intake of omega-6 fatty acid led to an increase in 9,10EpOME and PGA2 in young-SO mice compared with
young-LC mice, however was no change observed in
levels of 9,10-EpOME, PGA2, PGE2 and TXB2 between
aging-LC and -SO mice (Figure 3D). The heat map
cluster analysis and Z score analyses (Supplementary
Figure 5) showed that a total of 73 eicosanoids were
changed post-MI as an impact of age and fatty acids.
Nearly, ~90% of eicosanoids decreased as a result of
aging compared with young cohorts on normal diet. As
an impact of excess intake of fatty acids, there was an
increase in ∼80% of eicosanoids in SO-fed young mice
compared with young-LC post-MI. The aging mice did
not display much difference between the levels of
eicosanoids between LC and SO cohorts (Figure 3A).
These changes are represented in the Venn diagram,
which shows 40 AA eicosanoids were changed as a

Figure 1. Excess fatty acid influx depleted LOXs in young and aging post‐MI. (A) Study design indicating young
(6 months) and aging (18 months) mice on an omega‐6 fatty acids enriched safflower oil diet protocol. (B) No‐MI naïve
control and infarcted LV stained with periodic acid‐Schiff (PAS) at d1 post‐MI in young and aging, with and without fatty
acid enriched diet. No‐MI control represents the steady state naïve control mice (C) mRNA expression of LOXs (5,12,15)
and TNF‐α in infarcted LV. *p<0.05 vs young‐LC; $ p<0.05 LC vs SO. Values are means ±SEM; n=2‐4/group.
www.aging‐us.com
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result of aging. Only 6 AA eicosanoids were influenced
by the excess fatty acid intake and almost 27 AA
eicosanoids were changed as result of both age and fatty
acid (Figure 3B). Post-MI PCA analysis of young-LC,
young-SO versus aging-LC, aging-SO MI groups
showed a clear dissociation between excess fatty acid
supplied young vs aging cohorts (Figure 3C): Z-score
plots were constructed to identify metabolic changes
distinct to each group in response to MI (Supplementary
Figure 5). Thus, composition of lipid mediator milieu
affects LV healing through reduced levels of LOXs
expression and LOX-derived lipid mediators in post-MI
setting.
Excess intake of omega-6 fatty acids affects D-series
resolvins, protectin and maresin pre and post-MI
LOXs utilize omega-3 and omega-6 (arachidonic acid;
20:4n-6) as substrates in response to injury or infection
to form bioactive molecules [5, 10]. Omega-3 and -6
fatty acids exert protective effects on cardiovascular
system and their imbalance aggravates HF progression

post-MI [17]. Therefore, we further analyzed the DHA
metabolome in an excess of omega-6 environment. A
total of 21 DHA metabolites were detected in the
spleens of young and aging cohorts with excess omega6 fatty acid intake. There were minimal difference was
observed within the DHA metabolome when compared
between young and aging cohorts on normal diet. As an
impact of excess omega-6 intake, ∼90% of DHA
docosanoids decreased in both young and aging cohorts
pre- and post-MI. The Venn diagram shows aging
independently impacted 3 metabolites, while SO diet
group showed changes in 15 eicosanoids, and age with
excess fatty acid intake together impacted only 3
eicosanoids each (Figure 4A and B). Global PCA
analyses of DHA docosanoids showed that both youngLC and aging-LC clearly dissociate from each other
post-MI, but young-SO and aging-SO associate with
each other (Figure 4C). Regulation of DHA
docosanoids was diet-dependent in both pre- and postMI condition setting. Young and aging SO supplemented group decreased D-series pro-resolving bioactives 4,10-,14- HDHA, RvD5, 7(S)-maresin, protectin D1 (Fi-

Figure 2. Aging and intake of fatty acids impacts metabololipidomics profiling in LV healing. (A and B) Hierarchal cluster
analyses of lipids indicates increased levels of metabolites in young but decreased in SO diet fed aging group post‐MI. Color code
bar representing change in expression from green (‐1 lowest decrease) to red (+1 highest increase). (C) Venn diagram representing
the number of metabolites affected due to age (young vs aging) and SO diet post‐MI. (D) Principal component analysis (PCA) of lipid
metabolites suggesting limited intake of fatty acids in young and aging (LC) mice respond similar manner post‐MI; n =3/group.
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gure 4D and Supplementary Table 1). Thus, excess
intake of omega-6 fatty acids in aging affects the postMI resolution of inflammation by decreasing D-series
specialized pro-resolving bioactives.

decreased in aging-SO group. Thus, our results showed
that excess intake of omega-6 fatty acids impacted the
EPA metabolome in aging.
Excess fatty acid enhanced LV Ly6Chigh population
in aging-SO post-MI

Excess intake of omega-6 fatty acids decreased Eseries resolvins and their precursors

Post-MI, neutrophil and macrophage infiltration into the
infarcted LV dominates the early phase. There was no
difference observed in the neutrophil population
between the young and aging mice maintained on LC
diet, but the SO enriched group (young and aging)
displayed
recruitment
of
excess
neutrophils
(CD11b+/Ly6G+). The SO-fed groups showed a robust
increase the density of Ly6G+ cells in young
(19.5±1.8%) and aging (11.9±2.6%) mice post-MI d1.
Of note, the young-SO mice also displayed a higher
expression of CD11b+/Ly6G+ cells compared with
young-LC post-MI. No change was observed with
expression levels of CD11b+/Ly6G+ within aging-LC
and aging-SO mice post-MI (Figure 5A and 5C). In line
with previous post-MI leukocyte kinetics, the
monocytes differentiate to macrophages at the site of
injury; aging-LC mice showed slightly higher
percentage of CD11b+/F4/80+/Ly6Chigh (8.3±1.2%)
population compared to young-LC mice (6.4±1.6%) at
post-MI d1 (Figure 5B). The Ly6Chigh population at d1
post-MI was robustly increased in excess fatty acid-fed

In relation to AA-derived eicosanoids and DHA
derived-docosanoids, we also measured EPA-derived
bioactive(s) in both young and aging cohorts pre- and
post-MI. We found that none of the EPA eicosanoids
were impacted due to aging in mice. A total of 7
eicosanoids were changed due to an excess influx of
excess omega-6 intake. Age and diet both lead to the
change in 5 eicosanoids (Supplementary Figure 3A and
3B, Supplementary Table 1). PCA analyses and biplot
showed that all the four cohorts young-LC, young-SO,
aging-LC and aging-SO are separated from each other
(Supplementary Figure 3C and D, Supplementary Table
2). Similar to DHA docosanoids, ∼90% of the EPA
metabolome was decreased as a result of excess intake
of omega-6 fatty acid in both young and aging cohorts
post-MI. As shown in Supplementary Figure 3D, the
pro-resolving 8-, 9-,11-, and 18-HEPE were
significantly decreased in SO fed young and aging mice
post-MI. The precursor of E-series resolvin and RvE3
were increased in young-SO group, but significantly

Table 2. Brief description of fat and kcal/g that were supplemented to young
and aged mice for 2 months prior to MI and heart failure lipidome analysis.
Safflower oil
Groups

Standard Lab Chow (LC)
(SO)

Research diets

D10012M (AIN-93M)

D11102001

g%

g%

Protein

14

15

Carbohydrate

73

66

Fat

4

10

Omega-3 fatty acids

0.011

0.015

Omega-6 fatty acids

3.1

6.63

Omega-9 fatty acids

0.9

1.34

Kcal/g

3.8

4.2
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aging mice. The mononuclear cell population of youngSO fed mice (Ly6Chigh; 8.9±1.8%) were compared with
aging-SO fed mice (15.8±1.3%) (Figure 5D). Thus,
excess omega-6 enriched SO diet promotes
inflammation in aging, marked by an increase in
Ly6Chigh population post-MI.
Excess fatty acid intake in aging mice displayed dual
population of CD11b+/F4/80+ cells in infarcted LV
post-MI
LV analyses of CD45+/CD11b+ by flow cytometry
showed no difference in the percentage population LC
fed young and aging mice in no-MI controls. The SO
fed aging mice displayed higher percentage of
CD45+/CD11b+ (12.3%) cells compared to young-SO
(1.9%) in no-MI controls (Supplementary Figure 8E).
Post-MI, there was a global increase in CD45+/CD11b+
population due to excess intake of omega-6 fatty acids.
The SO fed young and aging mice displaying high per-

centage of CD11b+ cells i.e. 29.5±4.1% and 38.9±3.4%,
(Figure 5E and 5G) compared to LC-fed young and
aging cohorts, respectively. We noted a signature
population in the LV infarct of aging mice. The
infarcted LV of SO fed aging mice showed the dual
population of macrophages based on CD11b expression.
At d0, naïve controls and young-LC mice, displayed a
single population of CD11b+ cells, but aging LV
displayed dual population CD11blow/F4/80high and
CD11bhighF4/80high cells (Supplementary Figure 8H).
The young-SO mice showed a 3-fold increase in the
expression of CD11b+F4/80+ compared with young-LC
pre and post-MI. Post-MI, both LC and SO-fed aging
mice did not show any change CD11bhigh/F4/80high
percentage population (Figure 5F). There was a major
increase in CD11blowF4/80high (11.82±2.6%) cells in
aging-SO mice compared with aging-LC (6.32±3.4%)
mice (Figure 5G and H). Thus, excess omega-6 diet
aggravates macrophage population and expands them to
a dual macrophage population in aging post-MI.

Figure 3. Excess fatty acids in aging decreases arachidonic acid (AA) metabololipidome post‐MI. (A) Hierarchal cluster
analysis of change in AA metabolites due to young and aging with and without SO diet. Color code bar representing change in
expression from green (‐1 lowest decrease) to red (+1 highest increase). (B) Venn diagram representing the number of AA
metabolites affected due to age (young and aging) and SO‐diet post‐MI. (C) PCA analysis of AA metabolites of post‐MI with
respect to age and diet. (D) Bar graph representing change in AA metabolite production at pre‐MI (No‐MI controls) and d1 post‐MI.
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Figure 4. Excess omega‐6 fatty acids dysregulate DHA metabololipidomics profile post‐MI. (A) Hierarchal cluster
analysis of change in DHA metabolites in young and aging, with and without SO diet. Color code bar representing change in
expression from green (‐1 lowest decrease) to red (+1 highest increase). (B) Venn diagram representing the number of DHA
metabolites affected due to age (young and aging) and SO diet post‐MI. (C) PCA analysis of DHA metabolites with respect to age
and diet post‐MI. (D) Bar graph representing change in DHA metabolite production at pre‐MI (No‐MI controls) and d1 post‐MI.

Excess omega-6 intake aggravated MI-induced
cardiorenal inflammation
MI-induced cardiorenal inflammation is a multifactorial
situation in which the LV and kidney are simultaneously affected and their deleterious effects are reinforced in
a feedback cycle that aggravates progression of HF
[18]. Thus, we evaluated the markers of cardiorenal
inflammation in aging for the post-MI setting with and
without excess fatty acid intake. Pre-MI, apoptosis in
the kidney was examined by TUNEL method. The
standard diet fed young-LC and aging-LC mice did not
display any TUNEL positive cells. The excess intake of
omega-6 fatty acids increased TUNEL positive cells in
aging kidney, but not in young kidney (Figure 6A).
Compared to LC control, SO-fed aging mice showed
glomerulus expansion with elevated inflammation
(Figure 6B). Excess intake of fatty acid increased
plasma creatinine levels in SO-fed aging mice indicated
renal inflammation (Figure 6C). Post-MI renal inflam-
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mation due to excess intake of fatty acid in young and
aging mice was confirmed by upregulation of renal
injury and inflammation markers such as NGAL (4.5
fold young SO; 5.7 fold aging SO; p<0.01), Tnf-α (6.6
fold young SO; 1.7 fold aging SO; p<0.01), and IL-1β
(3.3 fold young SO; 2.2 fold aging SO; p<0.01)
compared with respective young LC pre-MI and at d1
post-MI (Figure 6C and D).
Aging decreased LV healing markers post-MI with
excess intake of omega 6 fatty acids
Post-MI receptor (FPR2/ALX) based biomolecule(s)
action and enzyme activation (5-LOX) with resolving
gene markers (Arg-1 and Ym-1) expression are essential
for early LV healing. Post-MI early expression of these
markers indicates resolution of inflammation. In no-MI
controls (d0), the FPR2/ALX and 5-LOX protein
expression was increased as an impact of aging (agingLC and aging-SO mice). Post-MI, SO-fed aging group

AGING (Albany NY)

showed decreased FPR2/ALX expression (FPR2/ALX0.5 fold, p<0.05 and 5-LOX -;1.5 fold, p<0.05)
compared with young-SO group. The excess influx of
fatty acid in aging decreased the expression of proresolving markers Arg-1 (2.7 fold; p<0.05) and Ym-1
(2.6 fold; p<0.05) in infarcted LV compared with
young-SO group (Supplementary Figure 2A and B).
Thus, excess intake of omega-6 fatty acids dysregulated
the infarcted LV healing markers post-MI in aging.

DISCUSSION
Non-resolving, overactive inflammation is the main
cause of post-MI ventricular dysfunction transition to
HF [5, 8]. Thus, it is essential to understand how lipid

signaling and molecular pathways are interlinked in the
non-resolving inflammatory milieu to develop a novel
therapeutic strategy for the treatment and prevention of
HF [8]. Here, we provide generation of a lipid
metabolite pathway that was previously technologically
unfeasible, showing the ability of LOX enzymes to
metabolize omega-6 fatty acids, which differentially
modify the leukocyte phenotype in young and aging
post-MI. With the application of LC-MS/MS
technology for the analyses of lipid mediators and flow
cytometry for analyses of immune cells, we revealed
that excess intake of omega-6 fatty acids: 1) decreases
LOXs activity to metabolize omega-6 fatty acids and
promotes inflammation in aging; 2) increases AAmetabolites in only young; 3) reduces specialized pro-

Figure 5. Excess intake of omega‐6 fatty acids increased F4/80+/Ly6Chigh Ly6G+, CD11b+ population post‐MI. (A)

Representative dot plots identifying CD11b+ population in LV mononuclear cells isolated from LC and SO fed young mice at d1
post‐MI. (B) Representative flow cytometry (FACs) dot plots showing Ly6Chigh in LV mononuclear cells isolated from LC and SO fed
young and aging mice at d1 post‐MI. (C) Bar graphs representing percentage of Ly6G+ population in LV mononuclear cells at d1
high
post‐MI. (D) Bar graphs representing percentage of Ly6C population in LV mononuclear cells at d1 post‐MI. (E) Representative
+
+
FACs dot plots showing CD45 /CD11b in LV mononuclear cells isolated from LC and SO fed young and aging mice at d1 post‐MI.
(F) Representative FACs dot plots showing CD11blow/F4/80high and CD11bhigh/F4/80high in LV mononuclear cells isolated from LC
+
and SO fed young and aging mice at d1 post‐MI. (G) Bar graphs representing percentage of CD11b population in LV mononuclear
cells at d1 post‐MI. (H) Histogram representing change in CD11b expression in young and aging mice post‐MI. *p<0.05 vs young‐
LC; $ p<0.05 LC vs SO. n=3‐5 mice/group for flow cytometry analysis.
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resolving D- and E-series resolvin biomolecules and
their precursors in young and aging; 4) increases
CD11blowF4/80high population in infarcted LV in aging
mice; and 5) drives cardiorenal inflammation in young
and aging (Figure 7). Moreover, we show that the nonresolving trigger is substrate-dependent (quality and
quantity) that determines chemokine/eicosanoids/docosanoids signaling and drives cytokine signaling in HF
pathology, indicated by increased TNF-α only in aging
post-MI. Despite the essential nature of omega-6 fatty
acids for health and homeostasis, in post-MI edematous
milieu, the most likely scenario is that the lack of
formation of biomolecules in aging drives the nonresolving inflammation that drives HF with increased
leukocytes (e.g. ↑Ly6Chigh and ↑CD11blowF4/80high) in
the infarcted LV (Figure 7).

Dysregulation of D- and E-series resolvins thereby
amplified inflammation post-MI
In the clinical setting, post-MI injury leads to the
development of LV dysfunction, as well as histological
and structural changes that account for HF due to
reperfusion therapy, but the triggers of this unknown
chemical remodeling presented a challenge in the 20th
century [19]. Using lipidomics technology, we
measured the AA, DHA, and EPA metabololipidome in
young and aging mice in relevance to excess omega-6
intake in a post-MI setting. We showed LOX (-5,-12,
and -15) mRNA expression was decreased in aging.
Likewise, docosapentaenoic acid metabololipidome was
also impacted in response to excess influx of omega-6
fatty acids. As the LOXs catalyze the transformation of

Figure 6. Post‐MI impact of fatty acids during aging on cardiorenal‐axis. (A) Immunofluorescence images representing
TUNEL positive cells (green) in young and aging‐SO fed mice. Nuclei are stained with propidium iodide (Red). (B) PAS staining
indicates granulomatous kidney inflammation. (C) Pre‐ and post‐MI plasma creatinine level and mRNA expression of TNF‐α and IL‐
1β, in kidney. (D) Pre‐ and post‐MI mRNA and protein expression of NGAL in kidney. *p<0.05 vs young‐LC; $p<0.05 LC vs SO.
Values are means ±SEM; n=; n=2 at d0, n=3‐4 at d1/group.
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free arachidonic acid into several pro-inflammatory and
pro-resolving products, the decrease in LOXs during
aging reduces the ability to form several eicosanoids/
docosanoids, which are essential to resolve post-MI
inflammation. Omega-6-derived products (HETEs,
HODEs, prostaglandins; PGs, thromboxanes; TXs and
leukotrienes; LTs and lipoxins) act as first line
chemoattractants/defenders
during
the
acute
inflammatory response. LOXs also metabolize omega-3
fatty acids into pro-resolving products (HEPEs,
monohydroxy-DHA and -EPA, further D- and E- series
resolvins) that turn on resolving mechanisms
overlapping with the acute inflammatory response [20].
Thus, an overall decrease LOXs expression in aging
imbalances the overall synchronous and transitional
cycle of the acute response to resolve inflammation
post-MI. The post-MI acute response activates PGs and
LTs, which are critical for wound healing, [8, 21] and
also overlap with tissue repair to activate the resolution
of inflammation process carried out by endogenously
biosynthesized chemical mediators such as lipoxins,
resolvins, protectins, and maresins [10, 21]. Excess
omega-6 fatty acid intake decreased specialized proresolving molecules like D- and E-series resolvins (e.g
RvD1, RvD5, RvE3) in young and aging mice. As a

result of lowered D-and E-series resolvins and their
precursors, there is a delay in the effective clearance of
leukocytes with increased levels of the cytokine, TNFα. Thus, imbalance of post-MI chemokine signaling
implicates the dysregulation of acute inflammatory
response in LV healing post-MI with intake of omega-6
fatty acids.
The role of essential omega-6 and conditional omega-3
fatty acids is well-established and they are important
biomarkers in HF and coronary heart disease [22-24].
The excess influx of omega-6 fatty acids in young mice
robustly increased the levels of AA eicosanoids pre- and
post-MI, but the aged mice failed to generate a similar
kind of response towards AA eicosanoidome post-MI.
In post-MI injury PGs, TXs and LTs are potent
chemotactic factors for leukocytes (neutrophils,
eosinophils and mononuclear cells) [21, 22, 25].
Cyclooxygenase (COX) -1 and -2 drives formation of
these molecules, but also forms prostacyclin having
antithrombotic property, therefore the inhibition of
COXs can induce MI events [25, 26]. With adverse
events from COX-2 inhibitors, it is understood that
formation of PGs, TXs, and LTs is essential to initiate
the post-MI acute inflammatory response in the infarc-

Figure 7. Schematic summary indicating the dysregulation of MI‐induced cardiorenal and
cardiosplenic network in aging.

www.aging‐us.com

2621

AGING (Albany NY)

ted area. AA metabolizes to PGs, TXs and LTs, which
aggravate pro-inflammatory response post-MI and at
same time, also forms epoxyeicosatrienoic acid (5-6-, 89, 11-12, 14-15 EETs) to balance inflammation with
activation of the cytochrome P450 epoxygenase
pathway [27]. Conventionally, PGs are considered proinflammatory, but recent evidence suggests that PGE2
acts as a stemoattractant, which promotes cardiomyocyte replacement post-MI. In a mesenchymal stem
cell transplant study, PGE2 downregulated leukocyte
proliferation in-vitro, decreased the number of cytotoxic
CD8+T cells in the infarcted myocardium, preserved
immune privilege, and restored cardiac function postMI [28, 29]. Thus, these first-line defenders are
essential during the acute phase of MI response, but the
interaction between the overabundance of substrate and
aging alters all lipid bioactive species and LOX
efficiency in LV healing post-MI. This demands longterm studies to determine the mechanisms of HF in
aging.
Splenocardiac and cardiospelnic link in post-MI
healing

and
Ly6Chigh
(pro-inflammatory
macrophages)
population that resist to clear due to an altered chemokine microenvironment that expands the innate phase
post-MI. Interestingly, the aging mice displayed a
distinct macrophage population (F4/80+) with high
levels of CD11b expression called (CD11bhigh). Since
CD11b expression is commonly associated with
neutrophils recruitment and monocytes, [26] the
persistent presence of F4/80+/CD11bhigh population in
aging mice without MI indicated a pro-inflammatory
environment results in low-grade inflammation and this
phenomenon has been termed as "inflammaging” [41] is
the primary cause of recurrent MI in HF. Young mice
fed excess fatty acids displayed higher expression of
CD11b compared with standard diet fed young mice
post-MI. This possibly could be due to an increase in
the number of AA eicosanoids within the milieu. Thus,
lifestyle-related post-MI setting opens a new avenue
and exciting opportunity to focus on post-MI eicosanoids or docosanoids levels and their leukocytic
receptors in future perspective studies to prevent the
progression of HF.
Post-MI cardiorenal syndrome in aging

Traditionally, ischemic heart disease is studied in a
vascular and in a cardiocentric manner. Recent evidence
suggest that MI-stimulates leukopoiesis, both in the
bone marrow and at the extramedullary splenic site [8,
30, 31]. In response to MI, 40% to 75% splenic
monocytes enter the blood stream and mobilize to the
infarct region to govern ischemic myocardium healing.
Clinical imaging confirms the translation of the
splenocardiac axis and metabolic activity using 18Ffluorodeoxyglucose, suggesting the link of metabolism
and inflammation in ischemic heart disease [30-32]. Our
previous report with chronic use of omega-6 fatty acids
promotes bone marrow adiposity in aging mice,
supporting the outcome of presented findings [11, 33].
Of note, there is dissension in the literature for the
source macrophages post-MI, which is either the yolk
sac and/or fetal liver [34] versus monocyte-derived
macrophages from the LV injury site replaces
residential macrophages with age [35]. Practically, the
use of fate mapping studies has limited translational
value because of the limited availability of human
hematopoietic, spleen and LV samples in a time
dependent manner for post-MI studies. The age-induced
dysregulation in the innate immune system has been
well established [36, 37]. The innate immune response
substantially alters with age, especially through dysregulation of pro-inflammatory cytokines such as
interleukin (IL)-6, IL-1β, TNF-α, and TGFβ, which lead
to chronic inflammation, and thus contribute to the
inflammaging phenotype, often observed in the elderly
[38-40]. The leukocyte response in both young and
aging groups showed high levels of Ly6G+ (neutrophils)
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Reports indicate that MI-induced advanced systemic
inflammation and renal dysfunction are accompanied by
worsening of renal failure leading to heart failure, and
mortality [42, 43, 18]. Our study suggests that an excess
fatty acid-enriched diet is the primary factor in renal
inflammation pre-and post-MI, with an observed
adaptive response in young and a maladaptive response
in aging groups. The elevated levels of plasma
creatinine in aging indicated the presence of renal
inflammation. The post-MI cardiorenal syndrome is
also present at the young age, however it cannot be
detected by plasma creatinine, as it is an unreliable
indicator of acute kidney injury. NGAL is commonly
used as an immediate marker of acute kidney inflammation [44, 45]. The immediate increase in NGAL
expression post-MI in the kidney in young age samples
with elevated levels of pro-inflammatory markers TNFα and IL-6 established the presence of cardiorenal
syndrome. Excess omega-6 fed mice showed renal
inflammation in aging is evident with an increase in
NGAL expression prior to MI. Thus, supplementation
of excess fatty acids aggravated post-MI to kidney
injury through further increasing the level of the proinflammatory chemokines and marked increase in
glomeruli apoptosis in aging.
Clinical translational perspective
Maintaining the optimal balance of inflammation is
crucial to successful post-MI LV healing [8]. Failure to
maintain this balance contributes to HF, which is
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characterized by persistent inflammation and failed
resolution influenced by lowered levels of pro-resolving
molecules like D- and E-series resolvins and lipoxins
[13]. In coronary heart disease and HF, the ratio of proresolving mediators (D-series resolvins, E-series
resolvin, EETs) to pro-inflammatory mediators (PGs,
LTB4, TXB2, tetranor-12-HETE) becomes imbalanced
and leads to non-resolving inflammation [8, 13, 27].
Although the mechanisms of the specific cell type and
receptor-interaction of these molecules in HF remain to
be elucidated, it is possible that some resolvins (e.g.
RvD1) may play a role through the activation of
leukocyte FPR2 receptor, as we described in our
previous report [5]. Of note, omega-3 fatty acids are
known for their cardiovascular benefit (1g/day) or to
reduce elevated triglycerides using higher doses (3-4
g/day) [46]. Although, the reports cannot be ignored
that indicate no benefit or rebuke cardiovascular benefit
that may stem from many factors such as aging, excess
omega-6 intake, anti-inflammatory treatment or
combination of these, which serve to modulate LOXs
lipid busting capacity, which needs to be investigated in
the future [26, 47, 48].
Study limitations
One limitation was the mice strain and sex, as we
studied only male C57BL/6J mice. Potentially lipid
metabolism and post-MI lipid remodeling is distinct in
female mice or other strains of mice with aging.
Another was that we studied 24h hr day one time point
post-MI. A time dependent long-term study would have
allowed us to correlate with chronic HF of clinical
setting. Further studies will be necessary to investigate
level of eicosanoids and docosanoids and their influence
on leukocyte phenotypes in time dependent manner in
order to promote healing and reduce cardiac
remodeling.
Taken together, age-associated decrease in lipid
processing enzymes (5-,12- and 15LOX) dysregulates
the formation pro-inflammatory and pro-resolving
molecules depending on the influx or availability of
substrate that tempers acute phase leading to promotion
or repression of inflammation post-MI.

METHODS
Animal compliance
All animal procedures were completed in compliance
with the “Guide for the Care and Use of Laboratory
Animals” (8th Edition, 2011), AVMA Guidelines for
the Euthanasia of Animals: (2013 Edition) and were
thereby approved by the Institutional Animal Care and
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Use Committees at the University of Alabama at
Birmingham, USA.
Mice and coronary ligation surgery
C57BL/6J mice 6 months (young) and 18 months
(aging) old were sourced from National Institute of
Aging colony (NIH, USA) and were maintained with
free access to water and diet under a constant
temperature of 19.8 - 22.2°C. Young adult and aging
mice were randomized into two groups and were 1) LC
(fed on standard lab chow, American Institute of
Nutrition 93M diet, 4% w/w fatty acids) and 2) SO (fed
on 10% w/w safflower-enriched diet) for 2 months
(Table 2). After 2 months, the young and aging groups
with and without SO diet were subjected to coronary
artery ligation surgery to induce MI (Fig. 1A, study
design). Non-surgery mice were maintained as d0 naïve
controls. To induce MI, mice were subjected to the
surgical ligation of the left anterior descending coronary
artery, as previously described [49]. The mice were
monitored after surgery until MI-d1 for necropsy.
LV function measurements using echocardiography
Vevo 770 (Visual Sonics Inc. Canada) in vivo imaging
system was used in order to perform echocardiographic
analysis with probes up to 40 MHz with a resolution of
30 µm. Prior to echocardiography, the mice were
anesthetized using 1.5-2.0% isoflurane in a 100%
oxygen mix. Using a surface electrocardiogram, the
heart rates and electrocardiogram were monitored.
Increased heart rates (heart rate >400 beats per minute)
were maintained during the acquisition to achieve
physiological measurements and short (M-mode) and
long axis (B-mode) images of hearts were obtained. The
measurements were taken in the mid-papillary region in
two dimensional parasternal long-axis and short-axis
recordings. Studies were performed prior to necropsy
for d0 naïve control mice as well as d1 post-MI young
and aging mice. Three images were obtained for each
variable from consecutive cardiac cycles. They were
averaged by operator-blinded to diet and age [49].
Necropsy
Young and aging mice with and without MI were
anesthetized under 2% isofluorane in 100% oxygen
mix. Blood was collected from the carotid artery 5
minutes post-heparin (4 IU/g; I.P.) injection and was
centrifuged in order to collect plasma. Plasma aliquots
were snap-frozen and stored at -80 °C for plasma
analysis. Lungs were collected, weighted, and processsed, as previously described. 2 To arrest the left and
right ventricles in diastole, they were perfused with
cardioplegic solution. The left ventricle was then
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dissected into three sections: (1) the remote region (LV
control: LVC), (2) the infarct region (LVI), and (3) the
LV mid-cavity. The LVC and LVI were stored for later
biochemical and LV mid-cavity histological and
immunohistochemistry (IHC) analysis. The spleen and
kidney were dissected via incision in the peritoneal
wall, were weighed and processed. The spleen was
divided into two halves. One half was fixed in 10% zinc
formalin for IHC and the other was flash frozen and
stored at -80 °C, and stored for later biochemical and
IHC analysis. The left kidney was longitudinally
dissected. One half of the left kidney was fixed in 10%
zinc formalin for IHC and the other was fixed in TissueTek® (Sakura Finetek, Torrence, CA, USA) for
immunocytochemistry. The right kidney was flash
frozen and stored at -80 °C for later biochemical and
IHC analysis [49].
Preparation of splenic protein for mass spectroscopy
15 mg of spleen tissue from young and aging; LC and
SO mice at day 1 post-MI was homogenized in 1:9 ratio
with 1X PBS (pH 7.4) and centrifuged at 10,000 rpm
for 5 min at 4°C. The supernatant was collected and
protein was measured using Bradford kit (Biorad Inc.).
LC-MS-MS analysis of splenic metabololipodomics
HPLC was performed on a C18 column (Luna, C18(2);
2.1×150 mm, 3 μm; Phenomenex), mounted on the
Prominence XR HPLC system (Shimadzu, Kyoto,
Japan). The mobile phase consisted of a gradient
between solution A, methanol-water-acetonitrile
(10:85:5 v/v/v), and solution B, methanol-wateracetonitrile (90:5:5 v/v/v), both containing 0.1%
ammonium acetate. The gradient program with respect
to the composition of solution B was as follows: 0–1
min, 50%; 1–8 min, 50–80%; 8–15 min, 80–95%; and
15–17 min, 95%. The flow rate was 0.2 ml/min. The
HPLC column was fully equilibrated to initial
conditions before each sample was injected. The HPLC
eluate was directly introduced to the electrospray
ionization source (TurboV) of the QTrap5500 mass
analyzer (AB Sciex, Framingham, MA, USA) in the
negative ion mode with the following settings: curtain
gas, 35 psi; GS1, 35 psi; GS2, 65 psi; temperature,
600°C; ion spray voltage, −1500 V; collision gas, low;
declustering potential, −60 V; and entrance potential, −7
V. The eluate was monitored by the multiple reaction
monitoring (MRM) method, to detect unique molecular
ion–daughter ion combinations for each of the 60
transitions with 8 ms dwell time for each transition and
5 ms settling time between scans. The total cycle time
was 1.625 s. Optimized collisional energies (18–35 eV)
and collision cell exit potentials (7–10 V) were used for
each MRM transition. The data were collected with
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Analyst 1.5.2 software (AB Sciex), and the MRM
transition chromatograms were quantitated by
MultiQuant software (AB Sciex). Concentration of each
detected analyte in splenic extract was calculated by
dividing the detected quantities (in nanograms) with
their corresponding molecular masses and reported as
nanomolar. Under standardized conditions, the
detection limits of most eicosanoids are 2 pg on the
column, and the limit of quantitation is 5 pg at a signalnoise ratio of 3. Since the sample volume used was 200
μl, this condition translates to an assay sensitivity of
0.03 nM for an average molecular mass of 330 of the
detected eicosanoids.
Post-MI metabololipidomics analysis using heat
maps, and principal component analysis
For generation of heat maps, the splenic-lipid mediators
(LM) concentration from young-LC, young-SO, agingLC and aging-SO from day 1 post-MI was normalized
by geometric mean for statistical significance. The
normalized values were used for generation of Venn
diagram, hierarchical cluster, and heat maps using
cluster 3.0 and java tree view software. Correlations
between young-LC, young-SO, aging-LC and aging-SO
groups was observed using principal component
analysis. The correlation-matrix was done using
Pearson (n) test to avoid inflating the impact of
variables with high variances on the PCA [5, 50].
Application of Z-score to AA, DHA and EPA
metabolome
In order to calculate z-scores the LMs were averaged for
young-LC, young-SO, aging-LC and aging-SO.
Standard z-score indicated how many standard
deviations a measured value is above or below the
mean. The higher the absolute value of the z-score, the
more the values deviates from the mean and it indicates
the significance of change in concentration. We report
the significance score (p<0.05) as the absolute value of
the z-score, so a significantly eicosanoids/docosanoids
might be up- or down-regulated in a sample.
LV, spleen and kidney RNA isolation and real-time
PCR
Post-necropsy, frozen LV (remote and infarct), spleen
and kidney samples were processed for RNA extraction.
Briefly, tissue was homogenized with a sonic
dismembrator (Fisher Scientific) at amplitude between
10 and 100 Hz in 500 µL TRIzol (Invitrogen). RNA
was then extracted and isolated. cDNA synthesis was
performed using 2 µg of total RNA using SuperScript®
VILO cDNA synthesis kit (Invitrogen, CA, USA).
Quantitative
PCR
(qPCR)
for
Alox-5
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(Mm01182747_m1), Alox-12 (Mm00545833_m1),
Alox-15
(Mm00507789_m1),
tnf-α
(Mm00443258_m1), FPR2/ALX (Mm00484464_s1), il1β (Mm01336189_m1), arg-1 (Mm00475988_m1), ym1 (Mm00657889_m1), ccl2 (Mm00441242_m1), ngal
(Mm01324470_m1), grp40 (Mm00809442_s1) was
done using TaqMan probes (Applied Biosystems, CA,
USA) on master cycler ABI, 7900 HT. Gene levels
were normalized to hypoxanthine phosphoribosyltransferase (Hprt-1; Mm03024075_m1). Data was
reported and analyzed as 2-ΔCT (ΔΔCT) values.
Protein extraction and immunoblotting
LV infarct tissues were weighted and placed in their
respective 1.5 mL tubes with 16 µl of 1xPBS (without
calcium, Invitrogen) and 1x proteinase inhibitor (Roche
Diagnostics). While at 4°C, the samples were dismembrated in short, 10 second intervals using a sonic
dismembrator until homogenous, then centrifuged at
maximum speed (14,000 rpm). The supernatant was
used as the soluble protein fraction. The kidney protein
was extracted using RIPA buffer. Total protein
determined with Bradford assay. Electrophoresis of 10
µg of protein from each tissue with XT bis-tris-4-12%
gel (Bio-Rad Inc.) in MOPS buffer (Bio-Rad) was
performed. Samples were then transferred onto
nitrocellulose membrane (Bio-Rad Inc.) and a total
protein stain was performed with Pierce reversible
protein stain, nitrocellulose membrane kit (Thermo
Scientific Inc.). Each membrane was blocked for 1 hour
at room temperature with 5% non-fat milk powder (BioRad) dissolved in PBS-T and probed with primary
antibodies. Primary antibodies (FPR2/ALX 1:1000;
Ccl2 1:5000; arg-1 1:5000, GPR40 1:1000; 5LOX
1:1000) were probed overnight at 4°C, subsequently
washed with PBS-T, and a secondary antibody was
applied (Biorad). Proteins were detected using Femto
chemiluminescence detection system. Densitometry of
protein blots were assessed with ImageJ software (NIH,
USA).
LV, spleen and blood flow cytometry
Single mononuclear cells were isolated from LV, blood
and spleen from young-LC, young-SO, aging-LC and
aging-SO mice post-MI d1 and were analyzed by flow
cytometry with slight modification [4]. The cell count
for LV mononuclear cells or splenocytes was adjusted
to ~1-2 million cells/stain. Isolated cell suspensions
were finally suspended in 200 µl of 1:500Fc block and
incubated for 10 min on ice. A cocktail of fluorophorelabeled monoclonal antibodies in 2X concentration were
added for 30 min on ice as appropriate for each study.
We used CD45-PE (BD Biosciences), CD11b-APC,
F4/80-Percp (molecular probes), Ly6C-FITC (BD
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Biosciences), Ly6G-pacific blue (e-bioscience) in
cocktail. All population are primarily gated using
CD45+ markers for hematopoietic cells. Further, the
neutrophils were defined as CD11b+/Ly6G+ cells.
Activated macrophages were defined as the cells dual
expression CD11b (Mac-1) and F4/80+surface marker.
The monocytes/macrophages were also classified on the
basis of CD11b expression as CD11blow/F4/80high and
CD11bhigh/F4/80high. The macrophages (F4/80+) were
also classified as M1 (classically activated macrophages) and M2 (alternatively activated macrophages)
based on Ly6chigh and Ly6Clow respectively. Data were
acquired on BDTM LSRII Flow Cytometer and
analyzed with FlowJo software, version 7.6.3.
Histological analysis of kidneys using PAS staining
Young and aging no-MI d0 naïve controls and post-MI,
the kidneys were collected and weighed. Longitudinal
middle slice of the kidney, taken through the hilum, was
embedded in paraffin and stained with periodic acidSchiff (PAS) reagent. In control and post-MI PASstained sections, glomeruli were systematically
analyzed and levels of glomerulonephritis graded (from
0 to 4).4 Normal glomeruli were given a grade of 0,
glomeruli with 1–25% glomerulonephritis were given a
score of 1, those with 26–50% glomerulonephritis
scored a 2, those with 51–75% glomerulonephritis
scored a 3, and those with 76–100% glomerulonephritis
scored 4.
Statistical analyses
Data are expressed as mean and SEM. Statistical
analyses were performed using GraphPad prism 5. Twoway analysis of variance (ANOVA) was used for
comparisons between young-LC, young-SO, aging-LC
and aging-SO. The basic parametric tests applied to
metabolomics data and all the metabolites included in
study were taken above the range of detection limit.
Lipid metabolite below limit of detection excluded from
the analysis to eliminate false discovery metabolite
measurements. All immunoblotting densitometry data
were normalized to total protein/lane. p<0.05 was
considered as statistically significant.

ABBREVIATIONS
AA: Arachidonic acid; CD: Cluster of differentiation;
COX: Cyclooxygenase; DHA: Docosahexaenoic acid;
DPA: Docosapentaenoic acid; EETs: Epoxyeicosatrienoic acids; EPA: Eicosapentaenoic acid; HDHA:
Hydroxydocosahexaenoic acid; HEPE: Hydroxyeicosapentaenoic acid; HETEs: Hydroperoxyeicosatetraenoic acid; HODEs: Hydroxyoctadecadienoic acids; HF:
Heart Failure; IL-6: Interleukin 6; IL-1β: Interleukin-
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1beta; LC: Lab chow; LC-MS/MS: Liquid
chromatography mass spectrometry; LOX: lipoxygenase; LT: Leukotrienes; LV: Left ventricle; MI:
Myocardial infarction; NGAL: Neutrophil gelatinaseassociated lipocalin; PGs: Prostaglandins; Rv: Resolvin;
SO: Safflower oil; TNF-α: tumor necrosis factor alpha;
TX: Thromboxane.
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SUPPLEMENTARY MATERIAL

Figure S1. Excess omega‐6 fatty acid influx impacted LOXs mRNA expression in young and aging mice. (A)
mRNA expression of LOXs (5,12,15) and TNF‐α in LV of no‐MI naïve controls . (B) mRNA expression of LOXs (5,12,15) and
TNF‐α in remote myocardium (LVC) post‐MI. *p<0.05 vs young‐LC; $ p<0.05 LC vs SO. Values are means ±SEM; n=4/group.

Figure S2. FPR2/ALX, 5‐LOX and Arg‐1 decreases post‐MI due to excess intake of fatty acid during aging. (A)
Immunoblot representing FPR‐2/ALX, ARG‐1 and 5‐LOX protein expression at d0 control and post‐MI d1 in young and aging mice
with and without SO diet. (B) Pre‐ and post‐MI densitometric analysis of mRNA expression for FPR2/ALX, ARG‐1 and 5‐LOX. Total
protein is used as loading control; *p<0.05 vs young‐LC; $ p<0.05 LC vs SO Values are means ±SEM; n=2 at d0, n=3‐4at d1/group.
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Figure S3. Post‐MI dysregulation of EPA metabololipidome in response to age and excess omega‐6 fatty acids
intake. (A) Hierarchal cluster analysis of change in EPA metabolites due to young and aging, with and without SO diet. Color code
bar representing change in expression from green (‐1 lowest decrease) to red (+1 highest increase). (B) Venn diagram representing
the number of EPA metabolites affected due to age (young and aging) and diet post‐MI. (C) PCA analysis of EPA metabolites with
respect to age and diet post‐MI. (D) Bar graph representing change in EPA metabolite at pre‐MI (No‐MI) and d1 post‐MI.

SUPPLEMENTARY TABLE
Please browse the Full Text version to see the data
of Supplementary Table 1. Pre and post-MI lipid
mediators levels in spleen (ng/ 50 mg spleen tissue).
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Figure S4. Post‐MI changes in DPA metabololipidome profile in response to age and excess fatty acids influx. (A)
Hierarchal cluster analysis of change in DPA metabolites due to young and aging, with and without SO diet. Color code bar representing
change in expression from green (‐1 lowest decrease) to red (+1 highest increase). (B) Venn diagram representing the number of DPA
metabolites affected due to age (young and aging) and diet post‐MI. (C) PCA analysis of DPA metabolites post‐MI with respect to age
and diet post‐MI; n =3 mice per group. (D) Bar graph representing change in DPA metabolite at pre‐MI (No‐MI) and d1 post‐MI.
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Figure S5. Z‐score analysis of AA metabolites in young‐LC, young‐LC, aging‐LC and aging‐SO.

Figure S6. Z‐score analysis of DHA metabolites in young‐LC, young‐LC, aging‐LC and aging‐SO.
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Figure S7. Z‐score analysis of EPA metabolites in young‐LC, young‐LC, aging‐LC and aging‐SO.

Figure S8. Excess intake of fatty acids increased F4/80+/Ly6Chigh and Ly6G+ population prior to MI. (A)
Representative dot plots identifying the CD11b+ population in LV mononuclear cells isolated from LC and SO fed, young and old
mice at d0 (NoMI). (B) Representative flow cytometry (FACs) dot plots showing Ly6Chigh in LV mononuclear cells isolated from LC
and SO fed young and aging mice at d0 (No‐MI). (C) Bar graphs representing percentage of Ly6G+ population in LV mononuclear
cells at d0 (No‐MI). (D) Bar graphs representing percentage of Ly6Chigh population in LV mononuclear cells at d0 (No MI). (E)
Representative FACs dot plots showing CD45+/CD11b+ in LV mononuclear cells isolated from LC and SO fed young and mice at d0
(No‐MI). (F) Representative FACs dot plots showing CD11blow/F4/80high and CD11bhigh/F4/80high in LV mononuclear cells
isolated from LC and SO fed young mice at d0 (No‐MI). (G) Bar graphs representing percentage of CD11b+ population in LV
mononuclear cells at d0 (No‐MI). (H) Histogram representing change in CD11b expression in young and aging mice at d0 (No‐MI).
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Figure S9. Altered expression of CCL2 and GPR40 post‐MI in aging mice due to excess intake of omega‐6 fatty acids
in an infarcted LV. (A) Immunoblot representing CCL2 and GPR‐40 protein expression at control (d0) and post‐MI d1 in young and
aging mice, with and without SO diet. (B) Pre‐ and post‐MI densitometric analysis of CCL2 and GPR‐40 immunoblots. Pre‐ and post‐
MI mRNA expression of CCL2 and GPR40 in LV. *p<0.05 vs Young‐LC; $ p<0.05 LC vs SO. Values are means ±SEM; n=2‐4/group.

Figure S10. Effect of age and excess omega‐6 fatty acids on pro‐inflammatory gene expression in kidney
post‐MI d1. Pre‐ and post‐MI mRNA expression of (A) FPR2/ALX in kidney (B) Ccl2 in kidney. *p<0.05 vs young‐LC; $
p<0.05 LC vs SO. Values are means ±SEM; n=2‐4/group.
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